person · Reporting owner

HENDERSON MICHAEL THOMAS

Disclosed activity across 4 companies

Tapewire entity: 1951
SEC CIK: 0001779990

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BridgeBio Pharma, Inc.BBIO · Entity 3360	Chief Business Officer	December 15, 2020	December 17, 2020
Spyre Therapeutics, Inc.SYRE · Entity 2649	Director	June 22, 2026	June 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BridgeBio Pharma, Inc.

Report date December 15, 2020 · Filed December 17, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-04-01	Direct	4,456	Reported balance After 2020-12-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-12-15 · Grant · Acquired 4,456 · Balance 4,456 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2030-07-20	Direct	3,137	Reported balance After 2020-12-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-15 · Grant · Acquired 3,137 · Balance 3,137 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.80 · Expires 2030-09-29	Direct	2,199	Reported balance After 2020-12-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-15 · Grant · Acquired 2,199 · Balance 2,199 F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.

F2: 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F3: 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

F4: 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.

Spyre Therapeutics, Inc.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	68,606	Reported balance After 2026-06-22 transaction · row 1 1 source row Row 1 · 2026-06-22 · Sale · Disposed 20,000 · Balance 68,606 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA Sciences Acquisition Corp IV

Report date July 31, 2024 · Filed August 01, 2024

Section 16 reporting ended · disclosed 2024-08-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B ordinary sharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-07-31 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) ("HoldCo"), Aja Merger Sub 1 ("Merger Sub 1"), Aja Merger Sub 2, Inc. ("Merger Sub 2") and Adagio Medical, Inc. ("Adagio") (the transactions contemplated thereby, the "Business Combination"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share, on a one-for-one basis.

Apogee Therapeutics, Inc.

Report date September 03, 2026 · Filed September 03, 2026

Section 16 reporting ended · disclosed 2026-09-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-09-03 transaction · row 1 1 source row Row 1 · 2026-09-03 · Disposition to issuer · Disposed 920,941 · Balance 0 F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2033-12-18	Direct	Reported balance After 2026-09-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-03 · Disposition to issuer · Disposed 387,012 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.07 · Expires 2034-12-09	Direct	Reported balance After 2026-09-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-03 · Disposition to issuer · Disposed 357,036 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.78 · Expires 2036-01-02	Direct	Reported balance After 2026-09-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-03 · Disposition to issuer · Disposed 253,016 · Balance 0 F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option. F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.

F2: The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.

F3: Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2020 Filed Jan 7, 2020 02:30 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	SaleCommon Stock	1,500	$32.69	$49,034.10	Disclosure SEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,737 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $32.15 to $33.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7. F3 · balance_after: Includes 1,470 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionManagement Incentive Units · Derivative	5,364	$0.00	$0.00	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 9 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionManagement Incentive Units · Derivative	151,563	$0.00	$0.00	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 8 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F4 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionManagement Incentive Units · Derivative	8,420	$0.00	$0.00	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 7 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of January 1, 2017, such that the shares shall be fully vested on January 1, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionManagement Incentive Units · Derivative	8,420	$0.00	$0.00	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · derivative · entry 6 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 22, 2016, such that the shares shall be fully vested on March 22, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	PurchaseCommon Stock	7,000	$17.00	$119,000.00	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,767 Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	5,364	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	151,563	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of October 31, 2018, such that the shares shall be fully vested on October 31, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	8,420	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of January 1, 2017, such that the shares shall be fully vested on January 1, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document
July 01, 2019 Filed Jul 3, 2019 20:14 UTC	BridgeBio Pharma, Inc. BBIO · Entity 3360	Exercise / conversionCommon Stock	8,420	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-019144 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 22, 2016, such that the shares shall be fully vested on March 22, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.